The Schwab U.S. Dividend Equity ETF (SCHD) has been rated a buy following its 2026 reconstitution, which increased allocations to Health Care and Financials while reducing Energy exposure. These changes improved SCHD's balance sheet quality, return on equity (ROE), and growth potential, positioning it to outperform the broader market represented by the SPDR S&P 500 ETF Trust (SPY). SCHD now features a lower price-to-earnings ratio (20x vs. SPY's 27x) and higher ROE, supporting a projected long-term return on investment of 8.5–9.0%, compared to SPY's 5–6%. The fund's shift towards quality sectors offers a buffer against market volatility amid geopolitical tensions, making SCHD an attractive option for investors seeking both value and growth.
The SCHD ETF has returned just under 2% in the past month, outperforming the S&P 500 ETF (SPY) by nearly 1%. Year-to-date, about 30 SCHD holdings have more than doubled the returns of SPY, which has returned 9.8%. Additionally, 31 SCHD holdings are t...
The Schwab U.S. Dividend Equity ETF (SCHD) has gained 20% year-to-date, outperforming the S&P 500's 10% rise. SCHD focuses on large-cap companies with strong dividend histories and value metrics, avoiding mega-cap tech stocks that led recent market r...
